source
- Merck halts development of BTK inhibitor nemtabrutinib after safety concernsMerck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…
- Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cutsAt the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…